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Objectives. The purpose of our study was to assess the prog-
nostic importance of the amount of dysfunctional but viable
myocardium in revascularized patients with coronary artery dis-
ease (CAD) and left ventricular (LV) dysfunction.
Background. The amount of dysfunctional but viable myocar-
dium predicts the functional improvement after revascularization
and may offer more precise risk stratification of patients referred
for bypass surgery or coronary angioplasty.
Methods. Two hundred and seventy-four consecutive patients
with CAD and LV ejection fraction <240% underwent low-dose
dobutamine echocardiography for viability assessment. One hun-
dred and thirty-three of them were revascularized using either
coronary artery bypass surgery (118 patients) or coronary angio-
plasty (15 patients) and entered this study. To quantify the
amount of dysfunctional but viable myocardium, wall motion was
scored using 16-segment model. The dysfunctional segments were
defined as viable if they exhibited improvement in their thickening
by at least 1 grade with dobutamine infusion. The patients were
followed up for a mean period of 20 6 12 months (range, 2 to 48)
for cardiac mortality and nonfatal cardiac events including myo-
cardial infarction, unstable angina pectoris requiring hospitaliza-
tion and hospitalization for heart failure. Standard follow-up
echocardiography was performed 3 to 6 months after revascular-
ization.
Results. Twenty-nine patients exhibited a large amount of
dysfunctional but viable myocardium (>26 segments, group A), 60
patients had a small amount of dysfunctional but viable myocar-
dium (2 to 5 segments, group B) and 44 patients were found to
have dysfunctional myocardium irreversibly damaged (group C).
Similar prerevascularization LV ejection fractions of 35% 6 5%,
34% 6 4%, 36% 6 4% in groups A, B and C increased to 47% 6
6% (p < 0.01 vs. baseline, p < 0.01 vs. groups B and C), to 40% 6
5% (p < 0.01 vs. baseline) and to 37% 6 6% (p 5 NS vs baseline),
respectively, after revascularization. The greatest functional im-
provement after revascularization in group A patients was accom-
panied by a lower rate of cardiac events during follow-up (2 vs. 18
in group B, p < 0.05, and vs. 17 in group C, p < 0.01) and better
cardiac event-free survival according to Kaplan–Meier survival
analysis (p < 0.05 vs. groups B and C, respectively).
Conclusion. In revascularized patients with CAD and moderate
or severe LV dysfunction, the presence of a large amount of
dysfunctional but viable myocardium identifies patients with the
best prognosis.
(J Am Coll Cardiol 1998;32:912–20)
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In many patients with coronary artery disease (CAD), resting
left ventricular (LV) dysfunction is a consequence of myocar-
dial hibernation. The important attribute of hibernating myo-
cardium is its ability to restore its function to normal or near
normal after myocardial revascularization (1,2). However, such
viable metabolically active but dysfunctional myocardium rep-
resents an unstable substrate which is likely to lead to ischemic
events (3). Recent studies have repeatedly suggested that
patients with CAD and LV dysfunction with nonrevascularized
viable myocardium have a propensity to suffer later cardiac
events (3–7) and that revascularization improves their survival
(3,5–7). To date, there are no reports on the influence of the
amount of dysfunctional but viable myocardium assessed by
dobutamine echocardiography (DE) on long-term prognosis of
revascularized patients with CAD and LV dysfunction. Re-
cently, the strong correlation between the number of dysfunc-
tional segments with contractile reserve assessed by DE and
the improvement in LV ejection fraction (EF) after revascu-
larization was found (8). Because LV systolic function is known
From the 1st Internal Department, and *Center of Cardiovascular and
Transplant Surgery, Brno; †Internal Department of the Faculty Hospital Motol,
Prague; and ‡Internal Department of the Faculty Hospital, Ostrava, Czech
Republic for the participating centers; §All participants and centers are men-
tioned in the Appendix. This work was supported in part by grant from the
Ministry of Health of the Czech Republic, IGA, No. 4344-3. Presented in part at
the XIII World Congress of Cardiology, April 1998, Rio de Janeiro, Brazil.
Manuscript received February 25, 1998; revised manuscript received June 5,
1998, accepted June 12, 1998.
Address for correspondence: Dr. Jaroslav Meluzı´n, 1st Internal Department,
St. Anna Hospital, Pekarˇska´ 53, Brno, 656 91, Czech Republic. E-mail:
jtoman@med.muni.cz.
JACC Vol. 32, No. 4
October 1998:912–20
912
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(98)00324-6
to be the important predictor of survival in patients with CAD
(9–12), one can await the prognostic impact of the quantifica-
tion of the amount of dysfunctional myocardium with contrac-
tile reserve.
Thus, the purpose of our study was to assess the prognostic
value of the amount of dysfunctional but viable myocardium as
indicated by DE in revascularized patients with CAD and LV
dysfunction.
Methods
Patient selection. Patients with CAD and LV dysfunction
referred for coronary angiography and potential coronary
revascularization were prospectively enrolled between January
1994 and December 1997 in one center and between May 1995
and December 1997 in the other centers if they fulfilled the
following criteria: 1) LV EF #40% as assessed by echocardi-
ography; 2) luminal diameter narrowing $50% of at least one
major coronary artery; 3) no myocardial infarction (MI) or
unstable angina pectoris (AP) within 2 months before coronary
angiography; 4) the ability to evaluate regional wall motion
abnormalities of all 16 myocardial segments with echocardiog-
raphy; 5) no cardiac disease except CAD; 6) no cancer or
relevant liver or renal disease; 7) no need for aneurysmectomy;
and 8) sinus rhythm in electrocardiography. Two hundred and
seventy-four such consecutive patients underwent DE for
viability evaluation within 3 days after coronary angiography.
One hundred and thirty-nine of them were revascularized
based on clinical criteria (stable AP and/or multivessel CAD)
within the next 2 months. Six of them were excluded because of
inability to revascularize all vessels supplying dysfunctional but
viable myocardial segments.
Thus, 133 revascularized patients entered our study: 129
men and 4 women. The mean age of patients was 58 6 8 years
(range, 42 to 78), the mean LV EF 34% 6 5%. One hundred
and twenty-three (92%) had a history of MI, 58 (44%) were
treated for hypertension, 65 (49%) for hypercholesterolemia
and 36 (27%) for diabetes. All patients gave their informed
consent to DE and written consent to coronary angiography
and coronary artery bypass grafting surgery or coronary angio-
plasty. The study protocol was approved by the Institutional
Ethics Committee.
Coronary angiography. Selective coronary angiography
was performed in multiple views using standard techniques
during 1 to 2 days after hospital admission. The severity of
coronary stenoses was expressed as percent luminal diameter
narrowing. Significant CAD was defined as $50% diameter
stenosis of at least one major coronary artery.
Dobutamine and follow-up echocardiography. Standard
transthoracic echocardiography and DE were performed with
the patients in the left lateral decubitus position. After resting
images were obtained, dobutamine was administered intrave-
nously with an infusion pump at doses 5 and 10 ug/kg/min each
for 5 min. Parasternal long-axis view, parasternal short-axis
views at the base, papillary muscle and apex levels and apical 2-
and 4-chamber views were recorded at rest and at both doses
of dobutamine on VHS videotape for subsequent off-line
analysis. The electrocardiogram was monitored continuously
during dobutamine infusion and blood pressure was taken at
each stage. Beta-blocking agents were withdrawn 24 h before
the stress. Follow-up standard echocardiography was obtained
3 to 6 months (mean 4 6 1) after coronary revascularization.
Echocardiographic analysis. Regional wall motion was
evaluated using a 16-segment model recommended by the
American Society of Echocardiography (13). Myocardial seg-
ments were scored with the following scale: 1 5 normal or
hyperkinetic, 2 5 hypokinetic, 3 5 akinetic and 4 5 dyskinetic,
with scoring by visual analysis of systolic wall thickening. Wall
thickening was assessed at a distance of $1 cm from the
adjacent segment to minimize the effect of tethering (14,15). A
regional wall motion score (WMS) index was calculated as the
sum of scores for each segment divided by the total number of
segments. The dysfunctional segments were defined as viable if
they exhibited functional improvement of at least 1 grade with
any dose of dobutamine. A change from dyskinetic to akinetic
was not considered to be improved wall motion. The presence
of dysfunctional but viable myocardium was defined by the
presence of at least two such adjacent dysfunctional but viable
segments (8,16–18). The number of dysfunctional but viable
myocardial segments was used to quantify the amount of
dysfunctional but viable myocardium and to discriminate the
patients’ groups. For the purpose of matching myocardial
segments with coronary distribution in angiography, apical,
anterior, anteroseptal and midseptal segments were assigned
to the left anterior descending coronary artery territory, and
the remaining segments either to the right coronary artery or
to the left circumflex coronary artery bed (19).
End-diastolic and end-systolic frames from apical 4- and
2-chamber views were traced on a Kontron C200 (Munich,
Germany) image processing computer for LV volume evalua-
tion. Volume and EF were calculated as an average of three to
five consecutive heart cycles using the biplane Simpson’s
method recommended by the American Society of Echocardi-
ography (13). Regional wall motion analysis and EF calcula-
tions were performed off-line from videotapes in one center by
readers who were blinded to patients’ data. All volume calcu-
lations were done by one experienced echocardiographer
(J.M.). Regional wall motion was assessed by consensus of two
experienced observers (J.M., L.Sˇ.). Interobserver and intraob-
server variabilities of those readers have been published pre-
viously (8) and attained 93% concordance for the scoring of
Abbreviations and Acronyms
AP 5 angina pectoris
CAD 5 coronary artery disease
DE 5 dobutamine echocardiography
EF 5 ejection fraction
LV 5 left ventricular
MI 5 myocardial infarction
WMS 5 wall motion score
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800 segments and 92% concordance for identifying the pres-
ence of contractile reserve of 121 dysfunctional segments,
respectively. Intraobserver variability was concordant for wall
motion scoring in 769 of 800 segments (96%) and for the
presence of contractile reserve in 115 of 121 segments (95%),
respectively.
Coronary revascularizations. Coronary revascularizations
were performed within 2 months after coronary angiography.
Of 133 patients who entered the study, 118 patients underwent
coronary artery bypass grafting surgery and 15 patients under-
went coronary angioplasty. There was no MI or unstable AP in
the period between DE and revascularization.
Follow-up. After coronary revascularization, 16 patients
were followed up by mail and by contact with the treating
physician, the others were regularly followed up by an exam-
ining echocardiographer in 3- to 6-month intervals. The pa-
tients were followed up for cardiac mortality and nonfatal
cardiac events including MI, unstable AP requiring hospital-
ization and hospitalization for heart failure. Myocardial infarc-
tion was defined as a hospital admission for prolonged
(.20 min) chest pain, electrocardiographic changes and an
increase in plasma cardiac enzyme activity. Unstable AP was
defined by resting anginal symptoms requiring hospitalization
with parenteral nitrates and/or heparin therapy (no cardiac
enzyme elevation or new Q waves on the electrocardiogram).
Heart failure requiring hospitalization was identified by dys-
pnoe, need for intravenous inotropic and/or diuretic therapy
and by symptoms associated with left (rales on lung ausculta-
tion, S3 gallop) and/or right (neck vein distension, ankle
edema, hepatomegaly) heart failure. Cardiac events were
analyzed as: cardiac death alone for survival; cardiac death and
nonfatal MI for infarction-free survival; and cardiac death,
nonfatal MI, unstable AP requiring hospitalization and hospi-
talization for heart failure for event-free survival. The
follow-up data were available for all surviving patients. In the
case of patient death or cardiac event, admitting departments
or local physicians were contacted to elucidate exact reason for
hospitalization or cause of death. The mean follow-up period
was 20 6 12 months (range, 2 to 48).
Statistical analysis. To define the cutoff value for differ-
entiating groups of patients with a large and a small amount of
dysfunctional but viable myocardium, five numbers of dysfunc-
tional but viable myocardial segments (4, 5, 6, 7 and 8) were
tested to best discriminate those groups according to the risk of
developing cardiac events. Using the Fisher exact test, the
cutoff value of six dysfunctional but viable segments was found
to have the greatest statistical power for our stratification (p 5
0.02). Lower cutoff values four and five were not able to
discriminate groups with increased risk of developing cardiac
events (p 5 0.40 and 0.30, respectively). Thus, three groups of
patients were defined. Group A comprised patients with a
large amount of dysfunctional but viable myocardium (six and
more dysfunctional but viable myocardial segments); group B
included patients with a small amount of dysfunctional but
viable myocardium (two to five dysfunctional but viable seg-
ments); and group C comprised patients in whom dysfunc-
tional myocardium was irreversibly damaged. Clinical and
echocardiographic data are given as mean 6 SD for continu-
ous variables or as a number (percent) for categoric variables.
Comparisons were performed for groups A, B and C, for
echocardiographic parameters before and after revasculariza-
tion and for patients with or without cardiac events. Differ-
ences in continuous variables were tested using Mann–
Whitney or Wilcoxon tests; differences in categoric variables
were evaluated using chi-square test with Yates correction or
Fisher exact test, respectively. Kaplan–Meier survival curves
were used to compare the survival, infarction-free survival and
event-free survival in groups A, B and C. The differences
between survival curves were assessed by the Mantel–Cox test.
The Cox proportional hazards model was utilized to analyze
the relation between cardiac event-free survival and the fol-
lowing variables potentially relating to the patients’ prognosis:
the presence of a large amount of dysfunctional but viable
myocardium, sex, age, completeness and type of revasculariza-
tion (bypass grafting or angioplasty), number of revascularized
arteries, prerevascularization LV EF and end-diastolic and
end-systolic volume indexes. In this Cox model the stepwise
elimination with the presence of a large amount of dysfunc-
tional but viable myocardium forced in the first step was
performed. The Kaplan–Meier analysis and Cox proportional
hazards model were performed using the BMDP 1L and 2L
programs of the BMDP statistical package for PC, version PC
90 (20). A p value ,0.05 was considered significant.
Results
Patient characteristics. Based on the number of dysfunc-
tional but viable segments assessed by DE, the patients were
divided into three groups. Group A comprised 29 patients with
a large amount of dysfunctional but viable myocardium (six
myocardial segments or more). The mean number of dysfunc-
tional but viable segments was 7.4 6 1.7 (range, 6 to 11).
Group B comprised 60 patients with a small amount of
dysfunctional but viable myocardium (two to five segments).
The mean number of dysfunctional but viable segments was
3.4 6 1.2. Group C comprised 44 patients in whom dysfunc-
tional segments were irreversibly damaged. The baseline and
postrevascularization characteristics of individual groups are
shown in Tables 1 and 2, respectively. Hypercholesterolemia
was defined as serum cholesterol .250 mg/dl and obesity as
body mass index $30 kg/m2. The only difference between
groups was the greater number of revascularized arteries in
group A than in group C. Otherwise, the groups were similar
with respect to gender distribution, age, frequency of stable AP
or previous MI, occurrence of risk factors for CAD, number of
diseased coronary arteries, completeness and type of revascu-
larization, postrevascularization medication or any other vari-
ables potentially relating to patient prognosis. Twenty-one
patients after bypass surgery and six patients after coronary
angioplasty continued to have or developed mild AP after
revascularization. These patients were similarly distributed in
all three groups. Nine of them underwent only incomplete
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revascularization. Two patients (one each from groups B and
C) with proven restenosis underwent repeat coronary angio-
plasty. There was no need for repeat bypass surgery.
Echocardiography. Left ventricular EFs and WMS indexes
at rest before revascularization were 35% 6 5%, 34% 6 5%,
35% 6 4%, and 2.13 6 0.40, 2.17 6 0.46, 2.06 6 0.42,
respectively (all p 5 NS), for groups A, B and C. Correspond-
ing end-diastolic and end-systolic volume indexes reached 86 6
30, 84 6 21, 84 6 22 and 56 6 22, 56 6 17, 54 6 17,
respectively (all p 5 NS). Follow-up echocardiography was
obtained in 117 patients. It was not performed in 12 patients
who died within 4 months after revascularization, in 1 patient
with acute MI 2 months after bypass surgery and in 3 patients
for nonmedical reasons. Table 3 represents a comparison of
echocardiographic variables before and after revascularization.
Left ventricular EF, WMS index and end-systolic volume index
significantly improved only in groups A and B. However,
improvement in LV systolic function was significantly greater
in patients with a large amount of dysfunctional but viable
myocardium (group A).
Cardiac events. Of 133 patients studied, 31 (23%) suffered
a cardiac event. These comprised 2 events in 2 group A
patients, 18 events in 16 group B patients (1 patient had 2
episodes of unstable AP and the other suffered MI 3 days after
bypass surgery and hospitalization for heart failure 15 months
after bypass surgery) and 17 events in 13 group C patients (1
patient suffered 3 episodes of unstable AP and 2 patients had
2 hospitalizations for heart failure). The detailed characteris-
tics of cardiac events are shown in Table 4. Of 11 early cardiac
events (within 30 days after revascularization), 9 deaths oc-
curred on hospital days 1, 2, 3, 4, 7, 10, 17, 28 and 30,
respectively, after bypass surgery; both nonfatal MIs were
diagnosed on day 3 after bypass surgery. All patients suffering
cardiac events underwent bypass surgery except one group B
patient who had one episode of unstable AP and one group C
patient suffering MI 2 months after angioplasty. Of 9 patients
who died within 30 days after bypass surgery, five suffered MI
(one group A, one group C, and three group B patients) on
days 1, 1, 2, 3, and 4, respectively, after operation. The cause of
death of remaining patients was progressive heart failure. Of
five late deaths, the reasons were progressive heart failure in
two group B patients and sudden cardiac death in the remain-
ing three. As demonstrated in Table 4, the cardiac event rate
was significantly lower in patients with a large amount of
dysfunctional but viable myocardium (group A) than in the
remaining patients. This observation is in concordance with the
Kaplan–Meier event-free survival analysis (Fig. 1) confirming
significantly better event-free survival in group A than in
groups B and C (both p , 0.05), respectively. There was no
difference in event-free survival between groups B and C.
Concerning infarction-free survival (Fig. 2) and survival (Fig.
3), there were no significant differences among groups.
Determinants of cardiac events. Table 5 compares clinical
characteristics relating to patient prognosis and prerevascular-
ization echocardiographic variables in patients with or without
cardiac events. Those suffering cardiac events were more likely
to have lower LV EF and the absence of a large amount of
dysfunctional but viable myocardium; otherwise, the differ-
ences were not significant. However, for late follow-up results,
LV systolic function after revascularization may be more
important than prerevascularization functional values. Thus,
Table 6 represents the functional variables obtained 3 to 6
months after revascularization and their changes from prer-
evascularization values in patients without events or with late
cardiac events in whom follow-up echocardiography was ob-
tained. Patients without cardiac events exhibited significantly
greater functional improvement after revascularization than
those with late events, inducing greater difference in postrevas-
cularization functional variables between these two groups.
Analysis by the Cox proportional hazards model revealed two
independent predictors for cardiac event-free survival: the
presence of a large amount of dysfunctional but viable myo-
cardium (relative risk 5 0.257, chi-square 5 5.12, p 5 0.024)
and LV EF before revascularization, the predictive power of
Table 2. Patient Characteristics After Revascularization
Group A
(n 5 28)
Group B
(n 5 56)
Group C
(n 5 40)
Stable angina pectoris 7 (25) 14 (25) 6 (15)
Smoking 1 (4) 1 (2) 1 (3)
Duration of follow-up (months) 20 6 10 19 6 12 22 6 14
Medication
Aspirin 28 (100) 51 (91) 35 (88)
Beta-blocking agents 20 (71) 32 (57) 21 (53)
ACE inhibitors 20 (71) 43 (78) 29 (73)
Values are expressed as number (%) of patients or mean 6 SD. ACE 5
angiotensin-converting enzyme.
Table 1. Baseline Patient Characteristics
Group A
(n 5 29)
Group B
(n 5 60)
Group C
(n 5 44)
Men 29 (100) 56 (93) 44 (100)
Age (yr) 59 6 8 59 6 8 57 6 9
Previous history
Myocardial infarction 27 (93) 53 (88) 43 (98)
Stable angina pectoris 28 (97) 54 (90) 37 (84)
Systemic hypertension 10 (34) 30 (50) 18 (41)
Diabetes 8 (28) 13 (22) 15 (34)
Hypercholesterolemia 14 (48) 27 (45) 24 (55)
Smoking 15 (52) 35 (58) 27 (61)
Obesity 3 (10) 12 (20) 5 (11)
Coronary angiography
Single-vessel disease 1 (3) 2 (3) 2 (5)
Double-vessel disease 6 (21) 12 (20) 9 (20)
Triple-vessel disease 17 (59) 38 (63) 29 (66)
Left main disease 5 (17) 8 (13) 4 (9)
Revascularization
Complete 24 (83) 42 (70) 33 (75)
CABG 27 (93) 53 (88) 38 (86)
Coronary angioplasty 2 (7) 7 (12) 6 (14)
No. of revascularized arteries 2.8 6 0.8* 2.6 6 0.9 2.5 6 0.6
*p , 0.05 vs. group C. Values are expressed as number (%) of patients or
mean 6 SD. CABG 5 coronary artery bypass grafting surgery; No. 5 number.
915JACC Vol. 32, No. 4 MELUZI´N ET AL.
October 1998:912–20 PROGNOSTIC VALUE OF DYSFUNCTIONAL MYOCARDIUM
which was even stronger (relative risk 5 0.880, chi-square 5
14.98, p , 0.001). The amount of additional information
contributed by the other variables was not statistically signifi-
cant.
Discussion
This study was performed in patients with CAD and
moderate-to-severe chronic LV dysfunction. Such patients
have a poor prognosis which can be improved by coronary
revascularization (21,22). Because of risk of bypass surgery in
patients with severe LV dysfunction, stratification with respect
to postoperative functional improvement—and especially
prognosis—may be worthwhile. In patients with a large amount
of dysfunctional but viable myocardium, there is a supposition
of more pronounced functional improvement after revascular-
ization and probably better prognosis than in those having only
a small amount or no such myocardium. However, to our
knowledge the prognostic significance of the amount of dys-
functional but viable myocardium assessed by DE has not been
determined.
Prognostic importance of myocardial viability recognized
by DE. Dobutamine echocardiography is an established
method for detecting viable myocardium in patients with CAD
and LV dysfunction with very good sensitivity and specificity
for predicting wall motion improvement after coronary revas-
cularization (16–18,23–32). In addition, DE has been recently
shown to provide prognostic information in patients with both
acute MI (33,34) and chronic CAD with LV dysfunction (4).
Sicari et al. (33) demonstrated in 778 patients with a first
uncomplicated acute MI that the presence of myocardial
viability assessed by low-dose DE is prognostically important
and is associated with greater incidence of unstable AP during
follow-up. However, the presence of viability did not signifi-
cantly relate to the occurrence of hard events (death or
reinfarction). On the other hand, the presence of remote
ischemia with high doses of dobutamine identified patients at
increased risk of cardiac-related death or nonfatal MI. In that
study myocardial response to different doses of dobutamine
enabled the estimate of risk of various cardiac events. Using
multivariate analysis of clinical, angiographic and DE vari-
ables, Carlos et al. (34) revealed that the only independent
predictors of adverse outcome after acute MI were infarction
zone nonviability and ischemia/infarction at a distance. These
results differ from those of Sicari et al. (33) in the importance
of infarction zone nonviability for adverse outcome. The exact
reason for the discrepancy is not clear, but it may be caused by
the influence of infarct size (Sicari et al. included only first
uncomplicated acute MI) with increased risk of adverse events
in large infarcts with nonviable myocardium. Next, support for
the importance of viability evaluation was provided by Bo-
lognese et al. (35) who demonstrated progressive LV dilatation
in patients after reperfused acute MI with the absence of
residual infarct-zone viability.
In patients with chronic CAD and moderate or severe LV
dysfunction, there is agreement of increased risk of medically
treated patients with dysfunctional but viable myocardium
(3–7). Using DE, Williams et al. (4) identified increase of
cardiac events in patients with viable or ischemic myocardium
as compared with those with scarring. This report is in keeping
with results in similar studies using positron emission tomog-
raphy (3,5,6) or rest-redistribution single-photon emission
computed tomography (7). They concordantly proved that
patients with dysfunctional but viable myocardium who are
treated medically are at increased risk of cardiac events and
that revascularization improves their survival (3,5–7).
Table 3. Echocardiographic Results in Groups A, B and C Patients
Group A
(n 5 26)
Group B
(n 5 53)
Group C
(n 5 38)
b a b a b a
WMS index 2.10 6 0.40 1.63 6 0.37*†‡ 2.14 6 0.46 1.97 6 0.45* 2.01 6 0.39 2.02 6 0.40
LV EDV index
(ml/m2)
83 6 29 80 6 24 82 6 20 79 6 23 81 6 20 80 6 23
LV ESV index
(ml/m2)
54 6 21 42 6 14* 54 6 16 48 6 16* 52 6 14 50 6 18
LV EF (%) 35 6 5 47 6 6*†‡ 34 6 4 40 6 5* 36 6 4 37 6 6
b 5 before revascularization; a 5 after revascularization. *p , 0.01 vs. value before revascularization (b); †p , 0.01
vs. group B; ‡p , 0.01 vs. group C. Values are expressed as mean 6 SD. EDV 5 end-diastolic volume; EF 5 ejection
fraction; ESV 5 end-systolic volume; LV 5 left ventricular; WMS 5 wall motion score.
Table 4. Cardiac Events in Groups A, B and C Patients
Group A
(n 5 29)
Group B
(n 5 60)
Group C
(n 5 44)
Cardiac events within 30 days after
revascularization
Death 1 4 4
Nonfatal myocardial infarction 1 1 0
Late cardiac events
Death 0 4 1
Nonfatal myocardial infarction 0 0 2
Unstable angina pectoris 0 4 3
Hospitalization for heart failure 0* 5 7
Sum of cardiac events 2†‡ 18 17
*p , 0.05 vs. group C; †p , 0.05 vs. group B; ‡p , 0.01 vs. group C. Values
are expressed as number of events.
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Importance of quantification of the amount of dysfunc-
tional but viable myocardium. The main result of this study
was the fact that patients with a large amount of dysfunctional
but viable myocardium (group A) exhibited significantly less
cardiac events and better cardiac event-free survival than those
with a small amount (group B) or no dysfunctional but viable
myocardium (group C). Except for the small but significant
difference in the number of revascularized arteries between
groups A and C, the groups were comparable in all variables
listed in Tables 1 and 2 relating to the patients’ prognosis as
well as in parameters of LV systolic function before revascu-
larization (Table 3). However, they differed markedly in pos-
trevascularization LV systolic function, being the greatest in
patients with a large amount of dysfunctional but viable
myocardium. This is not surprising because the linear relation-
ship between the number of dysfunctional segments with
contractile reserve and functional improvement after revascu-
larization has been documented previously (8). These data
suggest that the beneficial influence of a large amount of
dysfunctional but viable myocardium on patient prognosis was
mediated probably through significant functional improvement
after revascularization. Recently, Pagley et al. (36) demon-
strated very similar results using rest-redistribution thallium-
201 scintigraphy to quantify the extent of myocardial viability.
They demonstrated that patients with low EF, multivessel
CAD and greater extent of viability have better short- and
long-term outcomes after bypass surgery than similar patients
with lesser amount of viability. In our study, patients with or
without cardiac events differed only in terms of LV EF and the
presence of a large amount of dysfunctional but viable myo-
cardium (Table 5), which were both found to be predictors of
cardiac event-free survival. Patients without events had mildly
but significantly greater LV EF before revascularization, which
is in concordance with previous reports (12,37). For long-term
follow-up results, however, the values of LV systolic function
after revascularization may add more valuable information
than prerevascularization values. In our study, the patients
without cardiac events were found to have significantly greater
functional improvement after revascularization than those
suffering late events, explaining greater differences in post-
revascularization functional parameters between these two
cohorts of patients (Table 6). The Kaplan–Meier event-free
survival curves provided further support for the major impact
on patient prognosis by LV systolic function after revascular-
Figure 2. Kaplan–Meier curves demonstrating infarc-
tion-free survival in groups A, B and C patients. There
were no significant differences among groups.
Figure 1. Kaplan–Meier curves showing sur-
vival free of cardiac events (including death,
nonfatal MI, unstable AP requiring hospitaliza-
tion and hospitalization for heart failure) in
groups A, B and C patients. Event-free survival
was significantly better in group A than in
group B or group C, both being p , 0.05.
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ization. Groups A, B and C with comparable values of pre-
revascularization LV EFs, WMS indexes and end-systolic
volume indexes exhibited similar rates of early postoperative
events. However, patients with marked postrevascularization
functional improvement (group A) were found to have better
event-free survival later after revascularization, and this trend
increased with time of follow-up. All these data support the
need for quantification of myocardial viability, because only
such an approach offers information on risk of patients re-
ferred for bypass surgery and enables prediction of LV systolic
function after revascularization which is a very important
factor influencing patients’ long-term survival. Such stratifica-
tion may add a reasonable tool for therapeutic strategy in
patients with CAD and severely depressed LV function in
whom both revascularization and cardiac transplantation are
methods of choice.
Study limitations. The number of patients in our study was
relatively small. In addition, we do not have exact information
on the extent of coronary revascularization, because follow-up
coronary angiography was not performed. However, angina
pectoris after revascularization was distributed in a similar
frequency in all groups and its incidence was relatively low,
taking into account the number of incomplete revasculariza-
tions; therefore, the different extent of revascularization is
unlikely to account for the differences in patients’ survival.
There are several limitations in identifying dysfunctional but
viable segments inherent in DE. In some patients, one may find
no postrevascularization improvement in the areas of myocar-
dium with mix of viable tissue and fibrosis even if such
myocardium may exhibit a positive response to catecholamine
stimulation. On the other hand, in patients with severe stenosis
of the coronary artery, even a low-dose of dobutamine may
induce ischemia with no improvement in systolic thickening
despite preserved myocardial viability. Moreover, echocardio-
graphic evaluation of regional wall motion is a subjective
Figure 3. Kaplan–Meier curves showing survival in
groups A, B and C patients. There were no significant
differences among groups.
Table 5. Clinical Characteristics and Echocardiographic Results of
Patients Without and With Cardiac Events
Without
Events
(n 5 102)
With
Events
(n 5 31) p
Men 101 (99) 28 (90) 0.060
Age (yr) 59 6 8 57 6 8 0.271
Previous myocardial infarction 96 (94) 27 (87) 0.363
No. of risk factors for CAD 1.9 6 1.0 2.1 6 1.2 0.381
Incomplete revascularization 23 (23) 11 (35) 0.226
Coronary artery bypass grafting
surgery
89 (87) 29 (94) 0.518
No. of revascularized arteries 2.6 6 0.8 2.7 6 0.8 0.594
No. of dysfunctional but viable
segments
3 6 3 2 6 3 0.129
Large amount of d.b.v.m. ($6
segments)
27 (26) 2 (6) 0.034
Small amount of d.b.v.m (2 to 5
segments)
44 (43) 16 (52) 0.532
No d.b.v.m. 31 (30) 13 (42) 0.328
No. of stenosed coronary arteries 2.7 6 0.6 3.0 6 0.6 0.063
Prerevasc. LV EF (%) 35 6 4 32 6 6 0.002
LV EDV index (ml/m2) 83 6 23 89 6 23 0.167
LV ESV index (ml/m2) 54 6 17 61 6 19 0.051
WMS index 2.09 6 0.43 2.25 6 0.42 0.117
Duration of follow-up (months) 20 6 12 20 6 14 0.893
Values are expressed as mean 6 SD or number (%) of patients. CAD 5
coronary artery disease; d.b.v.m. 5 dysfunctional but viable myocardium; No. 5
number; prerevasc. 5 prerevascularization. Other abbreviations as in Table 3.
Table 6. Follow-up Echocardiographic Results of Patients Without
Cardiac Events and Those With Late Cardiac Events
Without Events
(n 5 99)
With Late Events
(n 5 18) p
LV EF (%) 41 6 6 36 6 5 ,0.001
LV EDV index (ml/m2) 79 6 24 83 6 17 0.259
LV ESV index (ml/m2) 46 6 17 54 6 13 0.020
WMS index 1.87 6 0.44 2.14 6 0.39 0.013
D LV EF (%) 6 6 6 2 6 4 0.003
D LV ESV index (ml/m2) 7 6 12 1 6 11 0.076
D WMS index 0.20 6 0.28 0.03 6 0.26 0.020
Values are expressed as mean 6 SD. Abbreviations as in Table 3. D LV EF 5
LV EF after revascularization 2 LV EF before revascularization; D LV ESV
index 5 LV ESV index before revascularization 2 LV ESV index after
revascularization; D WMS index 5 WMS index before revascularization 2 WMS
index after revascularization.
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method that may be influenced by tethering (14,15) and
postoperative paradoxic septal motion (38). We attempted to
minimize these potential confounding influences by assessing
systolic thickening rather than motion and by performing
follow-up echocardiography more than 3 months after revas-
cularization (mean 4 6 1 months, range 3 to 6). Recently,
Afridi et al. (39) have shown that the prediction of functional
recovery after revascularization with DE depends on the type
of wall motion response observed during dobutamine infusion,
the best being for a biphasic response (improvement in wall
thickening of dysfunctional segments at low dose and worsen-
ing at high dose of dobutamine). The recommendation of this
study is to administer low as well as high doses of dobutamine
for the optimal prediction of postrevascularization functional
recovery. In our study, which started 2 years before publishing
these results, only low doses of dobutamine were applied.
However, many authors using the same methodology have
described very good sensitivities of 87%, 89%, 88%, 79%, 82%,
and specificities of 82%, 82%, 87%, 83%, 92%, respectively,
for the prediction of reversibility of wall motion after revascu-
larization (28–32). Thus, despite the limitations mentioned,
low-dose DE still represents a valuable tool for identifying
dysfunctional segments that will recover after revasculariza-
tion.
Conclusions. Our data suggest that in patients with CAD
and moderate or severe LV dysfunction referred for coronary
revascularization, the identification and, especially, the quan-
tification of dysfunctional but viable myocardium is of great
clinical importance. Patients with a large amount of dysfunc-
tional but viable myocardium (greater than or equal to six
myocardial segments assessed by DE) exhibit greater post-
revascularization improvement in LV systolic function and
better prognosis as compared with those with a small amount
or no dysfunctional but viable myocardium.
We acknowledge J. Polach, RNDr, for his help in statistical analysis.
Appendix
Centers and participants: 1st Internal Department, St. Anna Hospital, Brno,
Czech Republic: J. Meluzı´n, MD, PhD, L. Sˇpinarova´, MD, L. Groch, MD.
Center of Cardiovascular and Transplant Surgery, Brno, Czech Republic: J.
Cˇerny´, MD, Prof, M. Fre´lich, MD, PhD, F. Sˇteˇtka, MD. Internal Department of
the Faculty Hospital Motol, Prague, Czech Republic: J. Popelova´, MD, PhD.
Department of Cardiac Surgery of the Faculty Hospital Motol, Prague, Czech
Republic: T. Honeˇk, MD, PhD. Internal Department of the Faculty Hospital,
Ostrava, Czech Republic: R. Sˇtı´pal, MD, PhD. Cardiosurgical Department of the
Faculty Hospital, Ostrava, Czech Republic: J. Tosˇovsky´, MD, PhD.
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